ALX Oncology Holdings Inc (ALXO) stock
ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.97−0.03 (-3.47%)
Close on Nov 18, 2026Market cap $134.14MP/E –Yield –
ALX Oncology r&d expenses
Research and development expenses are spending on new products and technology.
ALX Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $61.83M, down 32.7% year over year. For fiscal 2025 it was $77.00M, down 33.8% from the year before. The highest annual figure on record is $141.80M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.00M | -33.8% |
| FY2024 | Dec 31, 2024 | $116.37M | -17.9% |
| FY2023 | Dec 31, 2023 | $141.80M | +44.1% |
| FY2022 | Dec 31, 2022 | $98.40M | +63.5% |
| FY2021 | Dec 31, 2021 | $60.17M | +107.8% |
| FY2020 | Dec 31, 2020 | $28.96M | +77.6% |
| FY2019 | Dec 31, 2019 | $16.31M | +44.7% |
| FY2018 | Dec 31, 2018 | $11.27M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.14M | -27.1% |
| Q1 FY2026 | Mar 31, 2026 | $13.61M | -43.0% |
| Q4 FY2025 | Dec 31, 2025 | $17.65M | -25.0% |
| Q3 FY2025 | Sep 30, 2025 | $17.44M | -34.1% |
| Q2 FY2025 | Jun 30, 2025 | $18.02M | -48.0% |
| Q1 FY2025 | Mar 31, 2025 | $23.89M | -24.7% |
| Q4 FY2024 | Dec 31, 2024 | $23.53M | -43.7% |
| Q3 FY2024 | Sep 30, 2024 | $26.47M | -42.2% |
| Q2 FY2024 | Jun 30, 2024 | $34.65M | +17.5% |
| Q1 FY2024 | Mar 31, 2024 | $31.72M | +28.1% |
| Q4 FY2023 | Dec 31, 2023 | $41.78M | +65.8% |
| Q3 FY2023 | Sep 30, 2023 | $45.77M | +55.8% |
| Q2 FY2023 | Jun 30, 2023 | $29.48M | +10.2% |
| Q1 FY2023 | Mar 31, 2023 | $24.76M | +45.0% |
| Q4 FY2022 | Dec 31, 2022 | $25.20M | +20.6% |
| Q3 FY2022 | Sep 30, 2022 | $29.38M | +61.3% |
| Q2 FY2022 | Jun 30, 2022 | $26.75M | +138.5% |
| Q1 FY2022 | Mar 31, 2022 | $17.07M | +73.3% |
| Q4 FY2021 | Dec 31, 2021 | $20.89M | +72.1% |
| Q3 FY2021 | Sep 30, 2021 | $18.21M | +241.9% |
| Q2 FY2021 | Jun 30, 2021 | $11.21M | +46.3% |
| Q1 FY2021 | Mar 31, 2021 | $9.85M | +157.3% |
| Q4 FY2020 | Dec 31, 2020 | $12.14M | +80.3% |
| Q3 FY2020 | Sep 30, 2020 | $5.33M | +141.1% |
| Q2 FY2020 | Jun 30, 2020 | $7.66M | +111.2% |
| Q1 FY2020 | Mar 31, 2020 | $3.83M | – |
| Q4 FY2019 | Dec 31, 2019 | $6.74M | – |
| Q3 FY2019 | Sep 30, 2019 | $2.21M | – |
| Q2 FY2019 | Jun 30, 2019 | $3.63M | – |
See a number that looks wrong?